Company Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform.
The company develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 which targets B7-H3 on the surface of advanced solid tumors; GTB-7550, a product candidate in development for the treatment of lupus and other autoimmune disorders.
GT Biopharma, Inc. entered a master services agreement with Cytovance Biologics, Inc. to perform biologic development and manufacturing services, and to produce and test compounds; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology.
The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017.
GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
| Country | United States |
| Founded | 1965 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Michael Breen |
Contact Details
Address: 315 Montgomery Street, 10th Floor San Francisco, California 94104 United States | |
| Phone | 415 919 4040 |
| Website | gtbiopharma.com |
Stock Details
| Ticker Symbol | GTBP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000109657 |
| CUSIP Number | 36254L209 |
| ISIN Number | US36254L3087 |
| Employer ID | 94-1620407 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael Martin Breen L.L.B. | Interim Chief Executive Officer and Executive Chairman |
| Alan Louis Urban CPA | Chief Financial Officer and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 14, 2025 | 424B3 | Prospectus |
| Mar 13, 2025 | EFFECT | Notice of Effectiveness |
| Mar 7, 2025 | D | Notice of Exempt Offering of Securities |
| Mar 6, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 26, 2025 | 8-K | Current Report |
| Feb 24, 2025 | RW | Filing |
| Feb 21, 2025 | 10-K | Annual Report |
| Feb 7, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 27, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 27, 2025 | 8-K | Current Report |